Palliative Care Considered Beneficial, Though Infrequently Used in Lung Cancer
A team of international investigators deployed a survey to understand the needs of patients with EGFR-positive lung cancer community.
A team of international investigators deployed a survey to understand the needs of patients with EGFR-positive lung cancer community.
The addition of durvalumab after chemoradiotherapy for treatment of stage III NSCLC was cost-effective compared with chemoradiotherapy alone.
A team of investigators sought to determine outcomes from combination low-dose carboplatin plus nab-paclitaxel with concurrent radiotherapy among elderly patients with advanced non-small cell lung cancer.
Continued approval of the indication was contingent upon establishing the superiority of Keytruda as determined by overall survival.
The approval was based on data from 3 randomized, placebo-controlled trials that included 245 adults with ES-SCLC.
Chemotherapeutic and biologic agents for the treatment of non-small cell lung cancer (NSCLC).
Although patient-reported outcomes measures were similar with lorlatinib and crizotinib in non-small cell lung cancer, more patients reported improvement in symptoms with lorlatinib.
A team of investigators sought to determine whether the timing of radiotherapy after induction chemotherapy affected survival in patients with locally advanced non-small cell lung cancer.
Investigators conducted a retrospective chart review that assessed data from patients with unresectable, stage III NSCLC to assess real-world survival outcomes associated with durvalumab.
A single-center cohort study assessed progression-free survival and overall survival in patients with advanced NSCLC who received palliative pembrolizumab therapy.